Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Elizabeth Nally

Back to Search
Nally E, Sordelli F, Kudva V, Basile G, Hughes DJ, Boleti E, Powles TB, Bex A et al. ( 2025 ) . 165P Adjuvant pembrolizumab for early-stage renal cell carcinoma: A real-world experience from two UK tertiary oncology centers . Immuno-Oncology Technology vol. 28 ,
Shah K, Bergerot PG, Castro D, Mercier B, Nally E, Ali A, Hutson TE, Bex A et al. ( 2025 ) . 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis . The Oncologist vol. 30 , ( Supplement_2 )
Wells JC, Membribes SC, Nally E, Jackson-Spence F, Lalwani SB, Graham C, Szabados BE, Powles TB ( 2025 ) . 3130eP Time commitment requirements for clinical trial participation in patients with metastatic urothelial carcinoma . Annals of Oncology vol. 36 ,
Bergerot CD, Cella D, Bergerot PG, Castro DV, Mercier BD, Nally E, Ali AA, Philip EJ et al. ( 2025 ) . Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma . European Urology Oncology vol. 8 , ( 5 ) 1295 - 1302 .
Membribes SC, Nally E, Jackson-Spence F, Graham C, Lalwani S, Szabados B, Powles T ( 2025 ) . Established and emerging biomarkers approaches in urothelial carcinoma . Expert Review of Anticancer Therapy vol. 25 , ( 11 ) 1235 - 1241 .
Nally E, Powles T ( 2025 ) . Perioperative durvalumab for muscle invasive bladder cancer: the start of a new chapter . Future Oncology vol. 21 , ( 20 ) 2561 - 2563 .
Bergerot CD, Bergerot PG, Castro DV, Mercier B, Nally E, Ali A, Hutson TE, Psutka SP et al. ( 2025 ) . Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 526 - 526 .
Nally E, Ainsworth G, Brown SR, Bergerot CD, Wells C, Young MN, Westerman T, Coca S et al. ( 2025 ) . Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 525 - 525 .
Wells C, Nally E, Jackson-Spence F, Coca S ( 2025 ) . Systemic therapy clinical trial participation in patients with bladder and kidney cancers . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 451 - 451 .
Semaan K, Nawfal R, Janjigian YY, Robert C, Peters S ( 2024 ) . Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types . The Lancet Oncology vol. 26 , ( JAMA Netw Open 7 2024 ) 161 - 164 .
Nally E, Young M, Wells C, Fairhead R, Baines K, Cheney-Lowe H, Jackson-Spence F, Powles T ( 2024 ) . Is HER2 the New NECTIN4 in Advanced Urothelial Cancer? . European Urology Focus vol. 10 , ( 2 ) 219 - 221 .
Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, Jackson-Spence F ( 2024 ) . Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge . Cancer Management and Research vol. 16 , ( 0 ) 467 - 475 .
Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T ( 2024 ) . NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors . Clinical Genitourinary Cancer vol. 22 , ( 3 )
Bergerot CD, Castro DV, Bergerot PG, Mercier BD, Nally E, Ali AA, Philip EJ, Buso M et al. ( 2024 ) . Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 365 - 365 .
Back to Search